Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by
exquisite specificity, long serum half-life, high affinity and immune effector functions. In this …

In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …

Natural killer (NK) cells have crucial roles in the innate immunosurveillance of cancer and
viral infections. They are 'first responders' that can spontaneously recognize abnormal cells …

The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or
obinutuzumab improved the therapy of B-cell malignancies even though the precise …

The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage
innate immune effectors through interactions mediated by their fragment crystallizable (Fc) …

Success with B cell depletion using rituximab has proven the concept that B lineage cells
represent a valid target for the treatment of autoimmune diseases, and has promoted the …

Emerging evidence suggests that FcγR-mediated cross-linking of tumor-bound mAbs may
induce signaling in tumor cells that contributes to their therapeutic activity. In this study, we …

CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin
lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal …

Several novel anti-CD20 monoclonal antibodies are currently in development with the aim of
improving the treatment of B cell malignancies. Mutagenesis and epitope mapping studies …

The'magic bullet'concept of specifically targeting cancer cells at the same time as sparing
normal tissues is now proven, as several monoclonal antibodies and targeted small …